$ $
-------------------------------------------------------------------------
REVENUES
Milestone revenue 552,650 -
Upfront and licensing fees 131,244 131,244
Management fees from ENI - 239,930
-------------------------------------------------------------------------
683,894 371,174
-------------------------------------------------------------------------
EXPENSES
Research and development 9,839,170 11,060,455
General and administrative 5,317,524 3,140,800
Amortization 6,823,259 9,563,274
Foreign exchange loss (gain) 6,875 (82,043)
Loss on disposal of capital assets and assets
held for sale 14,377 58,034
-------------------------------------------------------------------------
22,001,205 23,740,520
-------------------------------------------------------------------------
Loss before the following (21,317,311) (23,369,346)
Interest income, net 1,226,099 350,380
Equity loss in affiliate - (477,723)
Gain (losses) of company transferred under
contractual arrangement 400,000 (618,922)
-------------------------------------------------------------------------
Loss before income taxes (19,691,212) (24,115,611)
Future income taxes recovery
'/>"/>
| SOURCE Transition Therapeutics Inc. Copyright©2007 PR Newswire. All rights reserved |